Study #2016-0330
A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy
MD Anderson Study Status
Not Accepting
Treatment Agent
Eflornithine, Lomustine
Description
The purpose of this study is to compare the efficacy and safety of eflornithine in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has recurred/progressed after radiation and temozolomide chemotherapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Anaplastic Astrocytoma, Recurrent Anaplastic Astrocytoma
Study phase:
Phase III
Physician name:
Carlos Kamiya Matsuoka
Department:
Neuro-Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.